[go: up one dir, main page]

FR23C1014I2 - Composés chimiques - Google Patents

Composés chimiques

Info

Publication number
FR23C1014I2
FR23C1014I2 FR23C1014C FR23C1014C FR23C1014I2 FR 23C1014 I2 FR23C1014 I2 FR 23C1014I2 FR 23C1014 C FR23C1014 C FR 23C1014C FR 23C1014 C FR23C1014 C FR 23C1014C FR 23C1014 I2 FR23C1014 I2 FR 23C1014I2
Authority
FR
France
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1014C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucana PLC
Original Assignee
Nucana PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27772362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1014(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nucana PLC filed Critical Nucana PLC
Publication of FR23C1014I1 publication Critical patent/FR23C1014I1/fr
Application granted granted Critical
Publication of FR23C1014I2 publication Critical patent/FR23C1014I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR23C1014C 2003-07-21 2023-02-28 Composés chimiques Active FR23C1014I2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0317009.9A GB0317009D0 (en) 2003-07-21 2003-07-21 Chemical compounds
EP04743483.2A EP1646639B8 (fr) 2003-07-21 2004-07-20 Phosphoramidates de nucleotides comme agents contre le cancer
PCT/GB2004/003148 WO2005012327A2 (fr) 2003-07-21 2004-07-20 Composes chimiques
EP18201295.5A EP3486251A1 (fr) 2003-07-21 2004-07-20 Composés chimiques
EP16155811.9A EP3040340B1 (fr) 2003-07-21 2004-07-20 Composés chimiques

Publications (2)

Publication Number Publication Date
FR23C1014I1 FR23C1014I1 (fr) 2023-05-05
FR23C1014I2 true FR23C1014I2 (fr) 2024-02-09

Family

ID=27772362

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1014C Active FR23C1014I2 (fr) 2003-07-21 2023-02-28 Composés chimiques

Country Status (20)

Country Link
US (2) USRE47589E1 (fr)
EP (5) EP3904365B1 (fr)
JP (1) JP4923216B2 (fr)
AU (1) AU2004261455B2 (fr)
CA (1) CA2518115C (fr)
CY (5) CY1117960T1 (fr)
DK (4) DK3040340T3 (fr)
ES (4) ES2928202T3 (fr)
FI (1) FIC20230013I1 (fr)
FR (1) FR23C1014I2 (fr)
GB (1) GB0317009D0 (fr)
HU (4) HUE059970T2 (fr)
MX (1) MXPA05012606A (fr)
NO (1) NO333603B1 (fr)
NZ (1) NZ541974A (fr)
PL (4) PL3040340T3 (fr)
PT (4) PT3040340T (fr)
SI (2) SI2955190T1 (fr)
TR (1) TR201901246T4 (fr)
WO (1) WO2005012327A2 (fr)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
BR0312278A (pt) 2002-06-28 2007-06-19 Idenix Cayman Ltd éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
PL377342A1 (pl) 2002-11-15 2006-01-23 Idenix (Cayman) Limited Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
ES2470771T3 (es) 2002-12-12 2014-06-24 Idenix Pharmaceuticals, Inc Procedimiento para la producción de nucle�sidos ramificados en 2'
CN100503628C (zh) 2003-05-30 2009-06-24 法莫赛特股份有限公司 修饰的氟化核苷类似物
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
AU2005285045B2 (en) 2004-09-14 2011-10-13 Gilead Sciences, Inc. Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
WO2006063149A1 (fr) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides presentant une activite antivirale et anticancereuse
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
DE102006037786A1 (de) 2006-08-11 2008-03-20 Resprotect Gmbh Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
WO2007054100A2 (fr) * 2006-11-13 2007-05-18 Santaris Pharma A/S Phosphoramidates du nucléoside lna
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2014233579B2 (en) * 2007-03-30 2016-06-23 Gilead Sciences, Inc. Nucleoside phosphoramidate prodrugs
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
FR2922551B1 (fr) * 2007-10-17 2009-12-25 Univ Claude Bernard Lyon Prodrogues phosphoesters de la gemcitabine comme agents anticancereux
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
TW201031675A (en) * 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2480559B1 (fr) 2009-09-21 2013-07-03 Gilead Sciences, Inc. Procédés et intermédiaires pour préparer des analogues de carba-nucléoside 1'-substitués
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CA2804840C (fr) 2010-07-22 2018-09-11 Gilead Sciences, Inc. Procedes et composes pour traiter des infections a virus paramyxoviridae
US8871737B2 (en) 2010-09-22 2014-10-28 Alios Biopharma, Inc. Substituted nucleotide analogs
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9156874B2 (en) 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CN103403014B (zh) 2011-01-03 2016-07-06 河南美泰宝生物制药有限公司 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
PT3447061T (pt) * 2011-03-01 2021-12-23 NuCana plc Formulação farmacêutica que compreende um derivado de fosforamidato de 5-fluoro-2¿-desoxiuridina para utilização no tratamento de cancro
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
EP2755983B1 (fr) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Composés de carbonyloxyméthylphosphoramidate substitué et compositions pharmaceutiques servant à traiter les infections virales
HUE036588T2 (hu) 2011-09-16 2018-07-30 Gilead Pharmasset Llc Eljárások HCV kezelésére
WO2013056046A1 (fr) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Phosphates 3',5'-cycliques substitués de composés nucléotidiques purines et compositions pharmaceutiques pour le traitement d'infections virales
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583677A3 (fr) 2011-10-21 2013-07-03 Abbvie Inc. Procédés pour le traitement du VHC avec au moins deux agent antiviral à action direct, ribavirin mais sans interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
MX350810B (es) 2011-12-20 2017-09-20 Riboscience Llc Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc.
PE20141423A1 (es) 2011-12-20 2014-10-16 Hoffmann La Roche Derivados nucleosidos con sustitucion 2',4'-difluoro-2'-metilo como inhibidores de la replicacion del arn del vhc
CA2860234A1 (fr) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Analogues de nucleotide phosphorothioate substitue
WO2013142124A1 (fr) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Formes solides d'un promédicament nucléotidique thiophosphoramidate
WO2013142157A1 (fr) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
KR20170082650A (ko) 2012-03-28 2017-07-14 후지필름 가부시키가이샤 1-(2-디옥시-2-플루오로-4-티오-β-D-아라비노푸라노실)시토신의 염
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
WO2013177188A1 (fr) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
WO2013177219A1 (fr) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. Composés d'acide d-aminé contre les maladies hépatiques
HUE029038T2 (en) 2012-05-25 2017-01-30 Janssen Sciences Ireland Uc Uracil spirooxetan nucleosides
WO2013187978A1 (fr) * 2012-06-16 2013-12-19 Nanjing Molecular Research, Inc. Promédicaments de phosphoramidate et phosphonoamidate à double ciblage hépatique
TWI603966B (zh) 2012-08-13 2017-11-01 富士軟片股份有限公司 １－（２－去氧－２－氟－４－硫－β－Ｄ－阿拉伯呋喃糖基）胞嘧啶之合成中間體、及硫核苷之合成中間體以及彼等之製造法
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
WO2014052638A1 (fr) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters et malonates de promédicaments à base de s-acyl-2-thioéthyle (sate)
GEP201706723B (en) 2012-10-08 2017-08-25 Idenix Pharmaceuticals Llk 2'-chloro nucleoside analogs for hcv infection
EP2909222B1 (fr) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC Nucléosides 2', 4'-pontés pour l'infection par le vhc
SI3235824T1 (sl) * 2012-11-16 2019-08-30 University College Cardiff Consultants Limited Zmes rp / sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
EP2935304A1 (fr) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro-nucléosides pour le traitement du vhc
BR112014011938B1 (pt) 2013-01-31 2021-03-16 Gilead Pharmasset Llc composição farmacêutica na forma de um comprimido com uma combinação de dose fixa de dois compostos antivirais, forma de dosagem farmacêutica compreendendo a referida composição e uso da referida composição
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
WO2014137930A1 (fr) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Nucléosides de thiophosphate pour le traitement du vhc
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
EP2970357B1 (fr) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Pronucléotides de phosphoramidate d'acide aminé de 2'-cyano, azido et amino nucléosides pour le traitement du virus de l'hépatite c (vhc)
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
AU2014250764A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Deuterated nucleoside prodrugs useful for treating HCV
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
WO2014193663A1 (fr) 2013-05-16 2014-12-04 Riboscience Llc Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
JP6366693B2 (ja) 2013-05-16 2018-08-01 リボサイエンス・エルエルシー ４’−フルオロ−２’−メチル置換ヌクレオシド誘導体
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
PL3650014T3 (pl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Preparat złożony dwóch związków przeciwwirusowych
EP3057976A1 (fr) * 2013-10-17 2016-08-24 Medivir Ab Inhibiteurs de la polymérase du vhc
KR20160099090A (ko) * 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
CN106061959B (zh) 2014-02-18 2018-11-09 富士胶片株式会社 四氢噻吩骨架型糖化合物的制造方法及四氢噻吩骨架型糖化合物
JP6204223B2 (ja) 2014-02-19 2017-09-27 富士フイルム株式会社 チオピラノース化合物等の製造方法
CN103804446A (zh) * 2014-02-27 2014-05-21 苏州东南药业股份有限公司 一种3,5-二苯甲酰基-2-去氧-2-氟-2甲基-D-核糖-γ-内酯的制备方法
EP3131914B1 (fr) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC Nucléosides méthyle ou alcynyle substitués en position 3 pour le traitement du virus de l'hépatite c
MY186584A (en) * 2014-06-25 2021-07-28 Nucana Biomed Ltd Formulation comprising a gemcitabine-prodrug
RS60968B1 (sr) * 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
WO2016012781A1 (fr) * 2014-07-22 2016-01-28 Nucana Biomed Limited Procédé pour la préparation de gemcitabine- [phényl (benzoxy-l-alaninyl)] phosphate
CN111269264A (zh) * 2014-08-25 2020-06-12 美迪维尔公司 用于治疗癌症的尿苷的二氧戊环类似物
WO2016033164A1 (fr) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Dérivés de nucléosides et de nucléotides
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
WO2016069975A1 (fr) * 2014-10-31 2016-05-06 Cocrystal Pharma, Inc. Analogues de 2',2'-dihalo-nucléosides utilisables en vue du traitement d'infections par des virus de la famille des flaviviridae et du cancer
WO2016073756A1 (fr) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Dérivés de nucléosides/nucléotides deutérés
LT3224268T (lt) 2014-11-28 2019-09-25 NuCana plc Naujieji 2` ir (arba) 5` aminorūgšties esterio fosforamidato 3`-deoksi adenozino dariniai, kaip priešvėžiniai junginiai
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN107428792B (zh) 2014-12-15 2023-01-24 埃默里大学 用于治疗乙型肝炎病毒的磷酰胺
WO2016134058A1 (fr) 2015-02-18 2016-08-25 Abbvie Inc. Combinaisons utiles pour traiter le virus de l'hépatite c
CA3182565A1 (fr) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. Nucleotides de purine ?-d-2'-desoxy-2'?-fluoro-2'-?-c-substitues-2-modifies-n6-substitues pour le traitement du virus de l'hepatite c
CA2975990A1 (fr) 2015-04-03 2016-10-06 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nouveau compose de 4'-thionucleoside, ainsi que son procede de preparation, composition pharmaceutique comprenant celui-ci et son application
HUE038541T2 (hu) * 2015-05-14 2018-10-29 NuCana plc Rák kezelési módszerek
TWI695841B (zh) * 2015-06-22 2020-06-11 瑞典商米迪維艾克提伯拉公司 治療癌症之前藥
WO2017040766A1 (fr) * 2015-09-02 2017-03-09 Abbvie Inc. Dérivés anti-viraux de tétrahydrofurane
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
MA52371A (fr) 2015-09-16 2021-09-22 Gilead Sciences Inc Méthodes de traitement d'infections dues aux coronaviridae
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN112156102B (zh) 2015-09-16 2023-10-03 济南高合医疗科技有限公司 一种nuc-1031单一异构体的晶型及其制备方法
PH12018500691B1 (en) * 2015-10-05 2022-08-10 NuCana plc Combination therapy
JP7019585B2 (ja) * 2015-11-16 2022-02-15 アヴァロ セラピューティクス，インコーポレーテッド 核酸プロドラッグ
MY196772A (en) 2015-12-11 2023-05-03 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
WO2017109444A1 (fr) 2015-12-23 2017-06-29 Nucana Biomed Limited Traitement combiné
CN108697725A (zh) * 2015-12-23 2018-10-23 努卡那有限公司 组合疗法
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
KR20190057277A (ko) 2016-06-24 2019-05-28 에모리 유니버시티 B형 간염 바이러스 치료용 포스포아미데이트
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
TWI787201B (zh) 2016-08-31 2022-12-21 日商富士軟片股份有限公司 抗腫瘤劑、抗腫瘤效果增強劑及抗腫瘤用套組
MY197236A (en) 2016-09-07 2023-06-07 Atea Pharmaceuticals Inc 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
JP2020518578A (ja) 2017-05-01 2020-06-25 ギリアード サイエンシーズ， インコーポレイテッド （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN109134568B (zh) * 2017-06-15 2022-11-22 北京美倍他药物研究有限公司 核苷磷酸酯/酰胺衍生物及其医药用途
ES3000461T3 (en) 2017-07-11 2025-02-28 Gilead Sciences Inc Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
US11266674B2 (en) 2017-09-01 2022-03-08 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Pharmaceutical composition for tumor treatment or prevention, method, and use thereof
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
KR102735678B1 (ko) 2017-09-21 2024-11-27 리보사이언스 엘엘씨 Hcv rna 복제의 억제제로서 4'-플루오로-2'-메틸 치환된 뉴클레오시드 유도체
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
TW201932119A (zh) 2018-01-29 2019-08-16 日商富士軟片股份有限公司 膽道癌用抗腫瘤劑和膽道癌的處理方法
JP2021512951A (ja) * 2018-02-02 2021-05-20 メイベリックス オンコロジー インコーポレイテッド ゲムシタビン誘導体の新規小分子薬物コンジュゲート
JP2021512953A (ja) 2018-02-02 2021-05-20 メイベリックス オンコロジー インコーポレイテッド ゲムシタビンモノホスフェートの小分子薬物コンジュゲート
JP6810763B2 (ja) * 2019-03-06 2021-01-06 ニューカナ パブリック リミテッド カンパニー がん治療
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
CN114641299A (zh) 2020-01-27 2022-06-17 吉利德科学公司 用于治疗SARS CoV-2感染的方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (fr) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Composés hautement actifs contre la covid-19
CN118994170A (zh) 2020-03-12 2024-11-22 吉利德科学公司 制备1'-氰基核苷的方法
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
KR20230028486A (ko) 2020-06-24 2023-02-28 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오시드 유사체 및 이의 용도
KR20220018954A (ko) * 2020-08-07 2022-02-15 주식회사 피노바이오 데옥시사이티딘계 항암제 및 실릴 에테르 함유 링커를 포함하는 접합체 및 이의 용도
FI4204421T3 (fi) 2020-08-27 2024-06-25 Gilead Sciences Inc Koostumuksia ja menetelmiä virusinfektioiden hoitoon
MX2024010591A (es) 2022-03-02 2024-09-06 Gilead Sciences Inc Compuestos y metodos para el tratamiento de infecciones virales.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US2945038A (en) 1956-09-26 1960-07-12 Hoffmann La Roche 5-fluorocytosine and preparation thereof
US3201387A (en) 1963-09-18 1965-08-17 Heidelberger Charles 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
FR2538397A1 (fr) 1982-12-24 1984-06-29 Charbonnages Ste Chimique Procede continu de fabrication d'homopolymeres ou de copolymeres de l'ethylene
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
DE69900841T2 (de) * 1998-01-23 2002-10-02 Newbiotics Inc., San Diego Durch enzymkatalyse erhaltene therapeutische substanzen.
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
CA2326535A1 (fr) 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides presentant une activite antivirale et anticancereuse
CN1390227A (zh) 1999-07-22 2003-01-08 新生物生物公司 酶催化的治疗活化
AU2451601A (en) 1999-12-23 2001-07-03 Newbiotics, Inc. Use of bvdu for inhibiting the growth of hyperproliferative cells
AU2002236455A1 (en) 2000-11-16 2002-05-27 Newbiotics, Inc. Synergistic ecta compositions
JP2004534830A (ja) 2001-06-21 2004-11-18 グラクソ　グループ　リミテッド Ｈｃｖにおけるヌクレオシド化合物
GB0129945D0 (en) * 2001-12-13 2002-02-06 Mrc Technology Ltd Chemical compounds
CN1646534A (zh) 2002-02-14 2005-07-27 法玛塞特有限公司 修饰的氟化核苷类似物
JP2005533817A (ja) 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド フラビウィルス科ウィルス感染治療用の修飾２′および３′−ヌクレオシドプロドラッグ
EP1567169A4 (fr) 2002-11-04 2009-10-21 Xenoport Inc Promedicaments de gemcitabine, leurs compositions pharmaceutiques et leurs utilisations
BRPI0407374A (pt) * 2003-02-19 2006-01-10 Univ Yale Análogos de nucleosìdeo antiviral e métodos para tratar infecções virais, especialmente infecções de hiv
CN100503628C (zh) 2003-05-30 2009-06-24 法莫赛特股份有限公司 修饰的氟化核苷类似物
SI3235824T1 (sl) 2012-11-16 2019-08-30 University College Cardiff Consultants Limited Zmes rp / sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
MY186584A (en) 2014-06-25 2021-07-28 Nucana Biomed Ltd Formulation comprising a gemcitabine-prodrug
WO2016012781A1 (fr) 2014-07-22 2016-01-28 Nucana Biomed Limited Procédé pour la préparation de gemcitabine- [phényl (benzoxy-l-alaninyl)] phosphate
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
HUE038541T2 (hu) 2015-05-14 2018-10-29 NuCana plc Rák kezelési módszerek
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
MY196772A (en) 2015-12-11 2023-05-03 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives

Also Published As

Publication number Publication date
AU2004261455A1 (en) 2005-02-10
JP2006528162A (ja) 2006-12-14
FR23C1014I1 (fr) 2023-05-05
DK2955190T3 (en) 2018-05-22
CY1117960T1 (el) 2017-05-17
TR201901246T4 (tr) 2019-02-21
EP1646639A2 (fr) 2006-04-19
SI2955190T1 (en) 2018-08-31
PT1646639T (pt) 2016-09-05
MXPA05012606A (es) 2006-02-08
US20060142238A1 (en) 2006-06-29
DK1646639T3 (en) 2016-09-12
NO20053993L (no) 2005-11-02
USRE47589E1 (en) 2019-09-03
PT3040340T (pt) 2019-02-06
PL1646639T3 (pl) 2016-12-30
HUE030374T2 (en) 2017-05-29
NZ541974A (en) 2009-03-31
CA2518115C (fr) 2012-03-20
PT3904365T (pt) 2022-10-13
NO20053993D0 (no) 2005-08-26
HUE059970T2 (hu) 2023-01-28
EP2955190B1 (fr) 2018-03-28
EP1646639B8 (fr) 2016-12-21
HUE042282T2 (hu) 2019-06-28
ES2928202T3 (es) 2022-11-16
EP1646639B1 (fr) 2016-08-17
PL2955190T3 (pl) 2018-09-28
CA2518115A1 (fr) 2005-02-10
ES2667698T3 (es) 2018-05-14
DK3040340T3 (en) 2019-02-25
WO2005012327A3 (fr) 2005-04-21
ES2589738T3 (es) 2016-11-16
CY2023008I1 (el) 2024-02-16
DK3904365T3 (da) 2022-10-17
NO333603B1 (no) 2013-07-22
EP3904365A1 (fr) 2021-11-03
GB0317009D0 (en) 2003-08-27
HUS2300012I1 (hu) 2023-03-28
EP3040340B1 (fr) 2018-11-14
PT2955190T (pt) 2018-05-07
CY2023008I2 (el) 2024-02-16
EP3486251A1 (fr) 2019-05-22
CY1120202T1 (el) 2018-12-12
ES2708570T3 (es) 2019-04-10
EP2955190A2 (fr) 2015-12-16
PL3904365T3 (pl) 2022-11-07
FIC20230013I1 (fi) 2023-03-01
CY1121218T1 (el) 2020-05-29
JP4923216B2 (ja) 2012-04-25
EP3904365B1 (fr) 2022-09-07
AU2004261455B2 (en) 2010-12-23
EP2955190A3 (fr) 2016-03-16
US7951787B2 (en) 2011-05-31
WO2005012327A2 (fr) 2005-02-10
EP3040340A1 (fr) 2016-07-06
CY1125603T1 (el) 2023-06-09
PL3040340T3 (pl) 2019-05-31
SI3040340T1 (sl) 2019-03-29

Similar Documents

Publication Publication Date Title
FR23C1014I2 (fr) Composés chimiques
SE0301569D0 (sv) Novel compounds
IS8108A (is) Ný efnasambönd
MA28912B1 (fr) Composes chimiques
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
MA28872B1 (fr) Composes chimiques
MA28814B1 (fr) Composes chimiques
IS8228A (is) Ný asetídínefnasambönd
MA28725B1 (fr) Composes chimiques
ITMI20021532A1 (it) Composti chimici
IS8292A (is) Ný efnasambönd
IS8089A (is) Efnasambönd
NO20031736D0 (no) Forbindelser
SE0303452D0 (sv) New compounds
SE0200465D0 (sv) Chemical compounds
SE0301425D0 (sv) Chemical compounds
SE0301385D0 (sv) Chemical compounds
SE0301370D0 (sv) Chemical compounds
SE0300499D0 (sv) Chemical compounds
SE0302155D0 (sv) Chemical compounds
SE0302162D0 (sv) Chemical compounds
SE0202656D0 (sv) Chemical compounds
SE0201706D0 (sv) Chemical compounds
SE0200327D0 (sv) Chemical compounds
SE0203821D0 (sv) Chemical Compounds